Search jobs
04-Aug-2021
Non-Surgical Basal Cell Carcinoma Treatment Is Predicted to Grow at a Staggering CAGR of 9% by 2025
Surgical treatment dominates with the highest revenue amongst all treatment options in the basal cell carcinoma treatment market, with a projected value of US$ 6 billion by the end of 2025. Mohs surgery is found to be an effective treatment for basal cell carcinoma (BCC), whereas, surgical excision accounts for the highest revenue amongst surgical treatment types.
Companies in the basal cell carcinoma treatment market are introducing improved formulations of molecular targeting agents approved by the FDA. For instance, vismodegib and sonidegib are two oral inhibitors approved by the FDA for the treatment of advanced BCC. A study published by the department of dermatology at the Keio University School of Medicine, Japan, stated that, antifungal drugs help to significantly reduce tumor size in BCC patients. Pharmaceutical companies in the basal cell carcinoma treatment landscape are increasing production capabilities of immune checkpoint inhibitors that are novel drugs with promising outcomes in patients associated with advanced melanomas. Patients are increasingly benefitting from these drugs, since they activate the body’s own immune system to destroy cancel cells.